Tyra Biosciences Inc (TYRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tyra Biosciences Inc (TYRA) has a cash flow conversion efficiency ratio of -0.091x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.62 Million) by net assets ($259.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View Tyra Biosciences Inc stock quote for real-time trading data and today's change.
Tyra Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tyra Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market cap of Tyra Biosciences Inc for the company's overall valuation and market capitalisation.
Tyra Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tyra Biosciences Inc ranked by their cash flow conversion efficiency. Also see Tyra Biosciences Inc (TYRA) total assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sk Gas
KO:018670
|
0.070x |
|
Sundaram Finance Holdings Limited
NSE:SUNDARMHLD
|
0.032x |
|
Pci-Suntek Technology Co Ltd
SHG:600728
|
0.008x |
|
Burkhalter Holding AG
SW:BRKN
|
0.638x |
|
Formula
TA:FORTY
|
0.230x |
|
PagSeguro Digital Ltd
NYSE:PAGS
|
0.032x |
|
American Superconductor Corporation
NASDAQ:AMSC
|
0.028x |
|
Anhui Shenjian New Materials Co Ltd
SHE:002361
|
0.019x |
Annual Cash Flow Conversion Efficiency for Tyra Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tyra Biosciences Inc from 2019 to 2025. Review TYRA financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $259.18 Million | $-95.14 Million | -0.367x | -80.54% |
| 2024-12-31 | $343.15 Million | $-69.77 Million | -0.203x | +17.16% |
| 2023-12-31 | $204.26 Million | $-50.14 Million | -0.245x | -25.86% |
| 2022-12-31 | $257.83 Million | $-50.28 Million | -0.195x | -147.84% |
| 2021-12-31 | $301.74 Million | $-23.75 Million | -0.079x | -113.82% |
| 2020-12-31 | $-13.64 Million | $-7.76 Million | 0.569x | +3.08% |
| 2019-12-31 | $-4.74 Million | $-2.62 Million | 0.552x | -- |
About Tyra Biosciences Inc
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. It… Read more